Figure 3.
Inhibition of SAD RBC adhesion on bEnd.3 endothelial cells by ICAM-4 peptide and by anti-αV integrin monoclonal antibody. Endothelial cell monolayers on microslides were treated by 250 μM T-8-I (ICAM-4 peptide) or A-8-C (control peptide), or 10 μg/mL anti-αV integrin antibody or control rat IgG, for 30 min before injection of RBC. (A) Adherence of SAD RBC on T-8-I peptide-treated endothelial cells. (B) Adherence of wild-type (WT) RBC on T-8-I treated endothelial cells. (C) Adherence of SAD RBC on endothelial cells treated with αV integrin antibodies. (D) Adherence of WT RBC on endothelial cells treated with αV integrin antibodies. ANOVA indicates that the differences observed for SAD RBC are highly significant (P< 0.001).